You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: July 13, 2025

Profile for China Patent: 102413825


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for China Patent: 102413825

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Apr 29, 2030 Amarin Pharms VASCEPA icosapent ethyl
⤷  Try for Free Feb 9, 2030 Amarin Pharms VASCEPA icosapent ethyl
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Analysis of Scope, Claims, and Patent Landscape for China Drug Patent CN102413825

Last updated: April 18, 2025

The Chinese patent CN102413825 represents a critical asset in the pharmaceutical sector, particularly for therapies targeting lipid disorders. This report provides a comprehensive analysis of its scope, claims, legal context, and position within China’s evolving patent landscape.


Patent Overview and Technical Scope

Pharmaceutical Composition and Therapeutic Use

CN102413825 is classified under IPC A61K31/202, which pertains to carboxylic acid esters used in medical formulations[1]. The patent’s inventive focus centers on ethyl eicosapentaenoate (EPA-E), a purified omega-3 fatty acid ethyl ester, formulated for treating mixed dyslipidemia—a condition characterized by elevated triglycerides and cholesterol[1][12]. The claims likely cover:

  1. Compound Claims: EPA-E as the active ingredient.
  2. Formulation Claims: Dosage forms such as softgel capsules (A61K9/48), often combined with stabilizers to prevent oxidation[1][16].
  3. Medical Use Claims: Specific indications, including cardiovascular risk reduction in patients with dyslipidemia[1][18].

The patent family includes counterparts in the US, Europe, and other jurisdictions, reflecting a global commercialization strategy[1]. The priority date of 29 April 2009 suggests a standard 20-year term in China, expiring in 2029[1][12].


Claim Structure and Legal Limitations

Narrowing Scope via Use Limitations

Chinese patent examiners often require medical use claims to include functional or indication-based limitations to satisfy novelty and inventive step requirements[16][18]. For CN102413825, this likely translates to claims restricted to:

  • Specific patient populations (e.g., diabetic patients with hypertriglyceridemia).
  • Dosage regimens (e.g., 1–4 grams daily)[1].
  • Combination therapies with statins or other lipid-lowering agents[1].

During prosecution, applicants may have amended claims to avoid prior art, potentially limiting enforcement to the approved indications and formulations[16]. For example, if the original claims broadly covered "a composition comprising EPA-E," examiners may have required narrowing to "a capsule comprising EPA-E for reducing cardiovascular risk in patients with mixed dyslipidemia"[1][16].

Risks of Overly Broad Functional Claims

The Federal Circuit’s Amgen v. Sanofi decision highlights the risks of broad, functionally defined claims lacking sufficient enablement[11]. While CN102413825’s compound claims are specific, formulation claims (e.g., "a stabilized composition") could face invalidation challenges if generic competitors demonstrate non-infringing alternatives[11][17].


China’s Patent Term Extension (PTE) Framework

Eligibility and Calculation

Under Article 42.3 of China’s Patent Law, CN102413825 may qualify for a PTE of up to 5 years if the drug obtained marketing approval (NMPA) after significant regulatory delays[3][12]. The PTE term is calculated as:
[ \text{PTE} = D{\text{MA}} - \text{Filing Date} - 5 \text{ years (max 5 years, total term ≤14 years post-approval)} ]
where ( D
{\text{MA}} ) is the approval date[3]. For instance, if the drug was approved in 2020, the PTE could extend protection to 2034[3][12].

Limitations on Protection Scope

During the PTE period, enforcement is limited to:

  • The approved drug product (e.g., specific EPA-E dosage form).
  • Approved indications (e.g., mixed dyslipidemia, not off-label uses)[3][12].

Patent Landscape and Strategic Considerations

Growth in Pharmaceutical Filings

China’s Belt and Road Initiative (BRI) has spurred cross-border IP collaboration, with Chinese applicants filing 70,000 patents in BRI countries from 2013–2023 (20% annual growth)[2]. Domestically, foreign pharmaceutical patents in China grew at 5.6% annually, driven by metabolic and cardiovascular therapies[2]. CN102413825 aligns with trends favoring lipid-modifying agents, a priority area given China’s rising diabetes prevalence[2][18].

Patent Linkage and Generic Challenges

China’s Orange Book system requires innovator patents to be listed for linkage enforcement[14][17]. Key implications for CN102413825:

  • Type 4.2 Declarations: Generic applicants may file declarations asserting non-infringement, triggering a 9-month stay on approval[17].
  • Litigation Trends: Courts often side with generics if claims are overly broad. In Chugai v. Haihe, amendments during prosecution limited scope, enabling generic entry[17].

Strategic Recommendations

Prosecution and Enforcement

  1. Drafting Claims: Convert dosing regimens into structural features (e.g., "a 1g capsule with enteric coating") to avoid invalidation[18].
  2. PTE Utilization: File for PTE within 3 months of NMPA approval to maximize exclusivity[3][12].
  3. Orange Book Listings: Register all relevant patents (composition, method, use) to deter generics[14][15].

Market Monitoring

  • Track generic filings via the NMPA’s Patent Information Platform[14].
  • Prioritize invalidation actions against high-risk generics[17].

Conclusion

CN102413825 exemplifies the interplay between China’s stringent claim requirements and evolving patent linkage system. While its compound claims provide robust protection, formulation and use limitations necessitate careful prosecution and enforcement strategies. The patent’s viability hinges on leveraging PTE, navigating litigation risks, and aligning with China’s regulatory priorities for innovative therapies.

References

  1. https://pubchem.ncbi.nlm.nih.gov/patent/US-2021100765-A1
  2. https://english.cnipa.gov.cn/module/download/downfile.jsp?classid=0&showname=13-Patent+Landscape_+China+and+Belt+and+Road+Partner+Countries+%282013-2023%29.pdf&filename=fbd6219df7de4ef8a817581c038eb211.pdf
  3. https://chinapatentstrategy.com/a-more-detailed-overview-of-chinas-patent-term-extension-pte-system/
  4. https://coincub.com/ranking/blockchain-patent-report-2023/
  5. https://docs.aws.amazon.com/cognito/latest/developerguide/cognito-user-pools-define-resource-servers.html
  6. https://learn.microsoft.com/en-us/entra/identity-platform/id-token-claims-reference
  7. https://brockallen.com/2019/02/25/scope-and-claims-design-in-identityserver/
  8. https://auth0.com/docs/get-started/apis/scopes/openid-connect-scopes
  9. https://auth0.com/docs/get-started/apis/scopes/sample-use-cases-scopes-and-claims
  10. https://www.thefdalawblog.com/2025/01/whats-in-a-claim-the-federal-circuit-rules-on-orange-book-patent-listings/
  11. https://dechert.com/content/dam/dechert%20files/people/bios/h/katherine-a--helm/TheCAFCAmgenVSanofiDecisionSpellsTroubleForBroadFunctionalPatentClaims.pdf
  12. https://www.twobirds.com/en/insights/2020/china/supplemental-protection-period-for-pharmaceutical-patents-in-china---update
  13. https://papers.ssrn.com/sol3/papers.cfm?abstract_id=2844964
  14. https://ipo.org/wp-content/uploads/2022/06/UNOFFICIAL-CN-Orange-Book-user-guide-Nov2022.pdf
  15. https://ipo.org/wp-content/uploads/2021/07/UNOFFICIAL-CN-Orange-Book-user-guide-final.pdf
  16. https://chinapatentstrategy.com/compositions-limited-by-use-a-cautionary-tale/
  17. https://www.iptechblog.com/2023/08/patent-linkage-litigation-in-china-a-two-year-review/
  18. https://www.juve-patent.com/sponsored/ccpit-patent-and-trademark-law-office/patenting-medical-use-inventions-in-china/

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.